|
| |
BioPortfolio's Approved Drugs DatabasePaclitaxelPaclitaxelDownload PDF containing detailed information.
Press Releases About Paclitaxel:
|
 |
| Oncolytics Biotech(R) Inc. Collaborators Present Positive Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting |
17th November, 2009 |
Oncolytics Biotech Inc. |
CALGARY, Nov. 17 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced updated results from a Phase I/II U.K.
|
| Oncolytics Biotech(R) Inc. Collaborators to Present Updated Phase I/II Trial Results in Advanced Solid Cancers with a Focus on the Head and Neck at the AACR-NCI-EORTC Meeting |
16th November, 2009 |
Oncolytics Biotech Inc. |
CALGARY, Nov. 16 /PRNewswire-FirstCall/ - Oncolytics Biotech Inc. (TSX:ONC, NASDAQ:ONCY) ("Oncolytics" or the "Company") today announced that a poster presentation covering updated
|
| Abbott's XIENCE PRIME(TM) and XIENCE V(R) Receive Indications in Europe for Treatment of Patients with Diabetes |
2nd November, 2009 |
|
BRUSSELS, November 2 /PRNewswire/ -- Abbott (NYSE: ABT) today announced that both the XIENCE PRIME(TM)
Everolimus Eluting Coronary Stent System(1) and the XIENCE V(R) Everolimus
Eluting Coronary Stent
|
| Video: Boston Scientific Announces European Approval and Launch of Platinum Chromium PROMUS(R) Element(TM) Stent System |
2nd November, 2009 |
Boston Scientific |
NATICK, Mass., Nov. 2 /PRNewswire-FirstCall/ -- Boston Scientific Corporation (NYSE: BSX) today announced it has received CE Mark for its PROMUS® Element(TM) Everolimus-Eluting Coronary Stent System,
|
| Boston Scientific Announces Results for Third Quarter Ended September 30, 2009 |
19th October, 2009 |
Boston Scientific Corporation |
-- Settled 14 outstanding patent litigation matters with Johnson & Johnson
"So far this year, CRM market growth has not been as strong as expected, but our CRM business has
|
Companies working in the area of Paclitaxel from Bioportfolio's Biocorporate database : | |
| Company Name | |
Angiotech Pharmaceuticals, Inc. is dedicated to the development of medical device coatings and treatments for chronic inflammatory diseases through the reformulation of the anticancer drug paclitaxel....
www.angiotech.com/ View full profile
| |
NeoPharm is a pharmaceutical Company engaged in the research and development of drugs for the diagnosis and treatment of various forms of cancer. Presently the Company has several drugs which are in...
www.neophrm.com/ View full profile
| |
NaPro BioTherapeutics, Inc. is a natural product pharmaceutical company focused primarily on the development, manufacture and commercializa tion of paclitaxel, a naturally-occurring anti-cancer agent...
www.naprobio.com/ View full profile
| | →View more Paclitaxel related companies. |
This page has been viewed 29 times
Browse BioPortfolio's InDepth service - alphabetically:
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z
or by Most Publications, recently searched for, or
most viewed.
Search for Paclitaxel across BioPortfolio, or for Paclitaxel Research Reports
Wikipedia excerpt, where present, licenced under the GNU Free Documentation License. Resources from the NCBI applied. Selected MeSH subject headings created and maintained by the US NLM are used in conjunction with additional keywords. 2006-2008 MeSH.
Thumbshots from Thumbshots.org
|
